GlassScriptPhysician profile
Negar Sodeifi
NPI 1437321429
$3,000.12
in general payments reported to CMS, 2019-2025
45 companies · $888 in 2025
The $888 reported for 2025 was more than what a typical Neurology (Psychiatry & Neurology) provider received nationally (typical 2025 total: $454).
See the full distribution for Neurology (Psychiatry & Neurology)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $192 · 2020: $220 · 2021: $234 · 2022: $340 · 2023: $430 · 2024: $697 · 2025: $888.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,014.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,014.29 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $481.13 | 2021-2025 | Qulipta, Ubrelvy, Botox |
| Lilly USA, LLC | $218.01 | 2023-2025 | Kisunla, Amyvid, Emgality |
| Alexion Pharmaceuticals, INC. | $174.79 | 2019-2025 | Ultomiris |
| Merz Pharmaceuticals, LLC | $169.73 | 2023-2025 | Xeomin, Inbrija |
| Novartis Pharmaceuticals Corporation | $146.97 | 2019-2025 | |
| Ucb, INC. | $146.60 | 2023-2025 | Nayzilam, Briviact, Zilbrysq |
| Livanova USA, INC. | $144.83 | 2022 | |
| Teva Pharmaceuticals USA, INC. | $114.37 | 2020-2024 | Austedo Xr |
| Genzyme Corporation | $79.11 | 2019-2023 | |
| Sk Life Science, INC. | $75.26 | 2024-2025 | |
| Amneal Pharmaceuticals LLC | $71.46 | 2019-2025 | Crexont |
| Allergan, INC. | $59.94 | 2020-2021 | |
| Octapharma USA, INC. | $57.27 | 2023 | Panzyga |
| Genentech USA, INC. | $55.88 | 2024-2025 | Ocrevus, Enspryng |
| Eisai INC. | $55.16 | 2023-2025 |
Show all 45 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Negar Sodeifi listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.